商品検索


メーカー名称:LKT Laboratories, Inc.
Metformin Hydrochloride
メーカー 品番 包装 希望販売価格 在庫 別包装/
セット品
販売状況
LKT
メーカー正式名称
LKT Laboratories, Inc.
M2076 100G ¥25,000
/
 
別名 Dimethylbiguanide hydrochloride; Imidodicaronimidic diamide; N,N-dimethyl-, monohydrochloride; N,N-Dimethylbiguanide hydrochloride, 1,1-Dimethylbiguanide Hydrochloride
納期目安 1週間程度
法規制 -
保存温度 常温
カテゴリ 化成品

内容:
純度 :>=98%
分子量 :165.62
CAS RN®: 1115-70-4
阻害剤の対象:AMPK activator.

使用目的: Metformin is an AMPK activator that exhibits anti-diabetic, antihyperglycemic, antioxidative, immunosuppressive, anticancer chemotherapeutic, anti-metastatic, and chemopreventive activities. Metformin modulates glucose-6-phosphatase activity, decreasing glucose production and glycogenolysis. Additionally, it inhibits expression of TNF-α in the liver, reversing pathology of fatty liver disease in vivo. In podocytes, metformin decreases activity of NADPH oxidase and generation of free radicals. In other in vitro models, metformin inhibits expression of MHC molecules and co-stimulatory factors on dendritic cells, preventing antigen presentation. Across several hepatocellular carcinoma cell lines, metformin decreases expression of cyclin D1, cyclin E, and CDK4, inducing G0/G1 phase cell cycle arrest and inhibiting cell proliferation. In vivo, this compound also downregulates expression of c-myc, preventing neoplasia initiation in prostate cancer models. Metformin’s activation of AMPK also inhibits Shh signaling in breast cancer models, suppressing proliferation, migration, and invasion.
構成内容: -
構造: C4H11N5 HCl
その他: [溶解性]100 mM water, 50 mM DMSO
[融点]223-226
参考文献: Fan C, Wang Y, Liu Z, et al. Metformin exerts anticancer effects through the inhibition of the Sonic hedgehog signaling pathway in breast cancer. Int J Mol Med. 2015 May 21. [Epub ahead of print]. PMID: 25999130.Miyoshi H, Kato K, Iwama H, et al. Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. Int J Oncol. 2013 Dec 30. [Epub ahead of print]. PMID: 24378856.Piwkowska A, Rogacka D, Jankowski M, et al. Metformin reduces NAD(P)H oxidase activity in mouse cultured podocytes through purinergic dependent mechanism by increasing extracellular ATP concentration. Acta Biochim Pol. 2013;60(4):607-12. PMID: 24432311.Akinyeke T, Matsumura S, Wang X, et al. Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis. 2013 Dec;34(12):2823-32. PMID: 24130167.Zhang Y, Guan M, Zheng Z, et al. Effects of metformin on CD133+ colorectal cancer cells in diabetic patients. PLoS One. 2013 Nov 21;8(11):e81264. PMID: 24278407.Shin S, Hyun B, Lee A, et al. Metformin Suppresses MHC-Restricted Antigen Presentation by Inhibiting Co-Stimulatory Factors and MHC Molecules in APCs. Biomol Ther (Seoul). 2013 Jan;21(1):35-41. PMID: 24009856.Chu CA, Wiernsperger N, Muscato N, et al. The acute effect of metformin on glucose production in the conscious dog is primarily attributable to inhibition of glycogenolysis. Metabolism. 2000 Dec;49(12):1619-26. PMID: 11145127.Lin HZ, Yang SQ, Chuckaree C, et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med. 2000 Sep;6(9):998-1003. PMID: 10973319.Minassian C, Tarpin S, Mithieux G. Role of glucose-6 phosphatase, glucokinase, and glucose-6 phosphate in liver insulin resistance and its correction by metformin. Biochem Pharmacol. 1998 Apr 15;55(8):1213-9. PMID: 9719475.Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995 Aug 31;333(9):550-4. PMID: 7623903.Nakamichi N, Shima H, Asano S, et al. Involvement of carnitine/organic cation transporter OCTN1/SLC22A4 in gastrointestinal absorption of metformin. J Pharm Sci. 2013 Sep;102(9):3407-3417. PMID: 23666872.

 画像1


※当社では商品情報の適切な管理に努めておりますが、表示される法規制情報は最新でない可能性があります。
 また法規制情報の表示が無いものは、必ずしも法規制に非該当であることを示すものではありません。
 商品のお届け前に最新の製品法規制情報をお求めの際はこちらへお問い合わせください。

※この商品の発注/見積依頼書の作成をご希望の場合は、下の[選択確認]ボタンをクリックしてください。
 選択を取り消す場合は、下の[選択の取消]ボタンをクリックしてください。